1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Rheumatoid Arthritis: Executive Summary

• 2.1 Biosimilar Erosion Will Temper Sales Growth in the RA Market from 2017-2027
• 2.2 Development of Novel Oral Agents and Biosimilars Are Popular R&D Strategies
• 2.3 Opportunities Remain for More Rapid, Targeted, and Cost-Effective Treatment for RA patients
• 2.4 Pipeline JAK1 Inhibitors Are Best Equipped to Penetrate the Crowded RA Market
• 2.5 What Do Physicians Think?

3 Introduction

• 3.1 Catalyst
• 3.2 Related Reports

4 Disease Overview

• 4.1 Etiology
• 4.2 Pathophysiology
• 4.3 Symptoms and Severity Classifications

5 Epidemiology

• 5.1 Disease Background
• 5.2 Risk Factors and Comorbidities
• 5.3 Global and Historical Trends
• 5.4 Forecast Methodology
• 5.5 Epidemiological Forecast for Rheumatoid Arthritis (2017-2027)
• 5.6 Discussion

6 Disease Management

• 6.1 Diagnosis and Treatment Overview
• 6.2 US
• 6.3 5EU
• 6.4 Japan
• 6.5 Australia

7 Competitive Assessment

• 7.1 Overview
• 7.2 Biosimilars in the RA Market

8 Unmet Needs and Opportunity Assessment

• 8.1 Overview
• 8.2 Earlier Diagnosis and Treatment
• 8.3 Cost-Effective Therapies
• 8.4 Personalized Treatment Strategies
• 8.5 Improved Guidance on Treating RA Patients in Remission

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising Drugs in Clinical Development
• 9.3 Other Drugs in Development

10 Current and Future Players

• 10.1 Overview
• 10.2 Trends in Corporate Strategy
• 10.3 Company Portfolio Assessments

11 Market Outlook

• 11.1 Global Markets
• 11.2 US
• 11.3 5EU
• 11.4 Japan
• 11.5 Australia

12 Appendix

• 12.1 Bibliography
• 12.2 Abbreviations
• 12.3 Methodology
• 12.4 Primary Research - KOLs and Payers Interviewed for This Report
• 12.5 Primary Research - Prescriber Survey
• 12.6 About the Authors
• 12.7 About GlobalData
• 12.8 Contact Us

Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2027

Summary

Rheumatoid arthritis (RA) is an autoimmune disease that, due to a complex interplay of environmental, immunological, and genetic factors, causes chronic inflammation and progressive deformity of the joints over time.

In 2017, the diagnosed prevalence of RA in the 8MM averaged 0.66% in adults 18 years of age and older and 2.7% in adults aged 60 and older. Early RA typically presents as a bilateral inflammatory joint condition, usually beginning in the smaller joints such as the fingers and toes and eventually progressing to the larger joints. Patients can experience flare-ups early in the disease onset, which are typically worse in the morning. Over time, pain and swelling may become constant, ultimately leading to deformity.

Key Question Answered

With the increased entry of biosimilars into the RA marketplace, sales growth has begun to slacken and will likely continue to slow over the next 10 years.
- How will biosimilar uptake differ cross the 8MM ?
- What companies and drugs will be most affected by sales erosion from biosimilars?

Key Opinion Leaders (KOLs) interviewed by GlobalData have indicated that there are still many remaining unmet needs within the RA indication.
- What are the main unmet needs in the RA market?
- How can the pharmaceutical industry address these needs?
- To what degree will the therapies under development fulfill these unmet needs?

Although biosimilars may slow the growth of the RA market, GlobalData expects that pipeline development of agents in the JAK inhibitor class as well as other novel oral agents , will powerfully shape the RA market going forward.
- What are the main R&D trends in the RA market and which companies are leading the way?
- Are there major differences in the mechanisms of action used by therapies in late-stage versus early stage clinical development?

Scope

- Overview of RA including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline RA therapeutics market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting RA therapeutics sales in the 8MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global RA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global RA therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global RA therapeutics market from 2017-2027.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.